Cybin prepares for gmp manufacturing of cyb003 capsules for phase 3 trial

Toronto--(business wire)--cybin inc. (nyse american:cybn) (neo:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced that it has initiated preparations for good manufacturing practices (“gmp”) production of a capsule formulation of cyb003, its proprietary deuterated psilocybin analog in development for the potential treatment of major depres.
CYBN Ratings Summary
CYBN Quant Ranking